Wiki-Pi

Search Results for: brca1

35 interactions involving BRCA1 - breast cancer 1, early onset found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CDK2 cyclin-dependent kinase 2
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Activation of the pre-replicative complex
  • Cellular Senescence
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • G2/M Transition
  • p53-Dependent G1/S DNA damage checkpoint
  • Activation of the pre-replicative complex
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • CDK-mediated phosphorylation and removal of Cdc6
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A/B1 associated events during G2/M transition
  • G2 Phase
  • Activation of ATR in response to replication stress
  • G1/S Transition
  • Removal of licensing factors from origins
  • Mitotic G1-G1/S phases
  • Switching of origins to a post-replicative state
  • G1/S DNA Damage Checkpoints
  • Meiotic recombination
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • DNA Replication Pre-Initiation
  • M/G1 Transition
  • Regulation of DNA replication
  • Senescence-Associated Secretory Phenotype (SASP)
  • G0 and Early G1
  • S Phase
  • Regulation of APC/C activators between G1/S and early anaphase
  • Factors involved in megakaryocyte development and platelet production
  • Cell Cycle, Mitotic
  • APC/C-mediated degradation of cell cycle proteins
  • SCF(Skp2)-mediated degradation of p27/p21
  • Orc1 removal from chromatin
  • Regulation of mitotic cell cycle
  • Cell Cycle Checkpoints
  • SCF(Skp2)-mediated degradation of p27/p21
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Double Oxidized Cysteine
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3\'-Monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • 5-{[(2-Amino-9h-Purin-6-Yl)Oxy]Methyl}-2-Pyrrolidinone
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(4-Trifluoromethyl-Phenyl)-Amine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Flavopiridol
  • (2e,3s)-3-Hydroxy-5\'-[(4-Hydroxypiperidin-1-Yl)Sulfonyl]-3-Methyl-1,3-Dihydro-2,3\'-Biindol-2\'(1\'h)-One
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • Alsterpaullone
  • N-[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)Pyrimidin-2-Yl]-N\'-Hydroxyimidoformamide
  • N\'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-CYCLOPROPYL-1H-PYRAZOL-5-YL)-2-(2-NAPHTHYL)ACETAMIDE
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4\'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDE
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3\'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • (2Z)-5\'-BROMO-2,3\'-BIINDOLE-2\',3(1H,1\'H)-DIONE AMMONIATE
  • (2S)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-{4-[(4-ANILINO-5-BROMOPYRIMIDIN-2-YL)AMINO]PHENOXY}-3-(DIMETHYLAMINO)PROPAN-2-OL
  • 2-IMINO-5-(1-PYRIDIN-2-YL-METH-(E)-YLIDENE)-1,3-THIAZOLIDIN-4-ONE
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N\',N\'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL
  • (2R)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2S)-1-[4-({4-[(2,5-DICHLOROPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • (2R)-1-[4-({6-[(2,6-DIFLUOROPHENYL)AMINO]PYRIMIDIN-4-YL}AMINO)PHENOXY]-3-(DIMETHYLAMINO)PROPAN-2-OL
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • 1-(DIMETHYLAMINO)-3-(4-{{4-(2-METHYLIMIDAZO[1,2-A]PYRIDIN-3-YL)PYRIMIDIN-2-YL]AMINO}PHENOXY)PROPAN-2-OL
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • (4-AMINO-2-{[1-(METHYLSULFONYL)PIPERIDIN-4-YL]AMINO}PYRIMIDIN-5-YL)(2,3-DIFLUORO-6-METHOXYPHENYL)METHANONE
  • N-METHYL-4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • N-METHYL-{4-[2-(7-OXO-6,7-DIHYDRO-8H-[1,3]THIAZOLO[5,4-E]INDOL-8-YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
  • 3-{[(2,2-DIOXIDO-1,3-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5-(1,3-OXAZOL-5-YL)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 4-{[(2-OXO-1,2-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(1,3-THIAZOL-2-YL)BENZENESULFONAMIDE
  • 3-{[4-([AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2-OXO-2,3-DIHYDRO-1H-INDOLE
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • 4-{[(2,6-dichlorophenyl)carbonyl]amino}-N-piperidin-4-yl-1H-pyrazole-3-carboxamide
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINE
  • 6-CYCLOHEXYLMETHYLOXY-2-(4\'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-ISOPROPYL-THIAZOL-2-YL)-2-PYRIDIN-3-YL-ACETAMIDE
  • 9-amino-5-(2-aminopyrimidin-4-yl)pyrido[3\',2\':4,5]pyrrolo[1,2-c]pyrimidin-4-ol
  • N-(3-METHYLBUT-2-EN-1-YL)-9H-PURIN-6-AMINE
ESR1 estrogen receptor 1
  • Nuclear signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB4
  • Diethylstilbestrol
  • Chlorotrianisene
  • Conjugated Estrogens
  • Etonogestrel
  • Desogestrel
  • Levonorgestrel
  • Progesterone
  • Raloxifene
  • Toremifene
  • Medroxyprogesterone
  • Estrone
  • Tamoxifen
  • Estradiol
  • Ethynodiol Diacetate
  • Clomifene
  • Dienestrol
  • Fulvestrant
  • Norgestimate
  • Ethinyl Estradiol
  • Melatonin
  • Trilostane
  • Naloxone
  • Fluoxymesterone
  • Estramustine
  • Mestranol
  • Danazol
  • Allylestrenol
  • Genistein
  • Compound 19
  • Compound 18
  • Compound 4-D
  • 1-[4-(Octahydro-Pyrido[1,2-a]Pyrazin-2-Yl)-Phenyl]-2-Phenyl-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • 2-Phenyl-1-[4-(2-Piperidin-1-Yl-Ethoxy)-Phenyl]-1,2,3,4-Tetrahydro-Isoquinolin-6-Ol
  • Estriol
  • Estropipate
  • Quinestrol
  • Ospemifene
  • 17-METHYL-17-ALPHA-DIHYDROEQUILENIN
  • 4-(2-amino-1-methyl-1H-imidazo[4,5-b]pyridin-6-yl)phenol
  • [5-HYDROXY-2-(4-HYDROXYPHENYL)-1-BENZOFURAN-7-YL]ACETONITRILE
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-8-METHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S,9R)-5-(HYDROXYMETHYL)-8,9-DIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • 4-[(1S,2S,5S)-5-(HYDROXYMETHYL)-6,8,9-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (2R,3R,4S)-3-(4-HYDROXYPHENYL)-4-METHYL-2-[4-(2-PYRROLIDIN-1-YLETHOXY)PHENYL]CHROMAN-6-OL
  • (3AS,4R,9BR)-2,2-DIFLUORO-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • (9ALPHA,13BETA,17BETA)-2-[(1Z)-BUT-1-EN-1-YL]ESTRA-1,3,5(10)-TRIENE-3,17-DIOL
  • (9BETA,11ALPHA,13ALPHA,14BETA,17ALPHA)-11-(METHOXYMETHYL)ESTRA-1(10),2,4-TRIENE-3,17-DIOL
  • 3-CHLORO-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • 3-ETHYL-2-(4-HYDROXYPHENYL)-2H-INDAZOL-5-OL
  • dimethyl (1R,4S)-5,6-bis(4-hydroxyphenyl)-7-oxabicyclo[2.2.1]hepta-2,5-diene-2,3-dicarboxylate
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • N-[(1R)-3-(4-HYDROXYPHENYL)-1-METHYLPROPYL]-2-(2-PHENYL-1H-INDOL-3-YL)ACETAMIDE
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
  • 4-[1-allyl-7-(trifluoromethyl)-1H-indazol-3-yl]benzene-1,3-diol
  • 4-(6-HYDROXY-1H-INDAZOL-3-YL)BENZENE-1,3-DIOL
  • DIETHYL (1R,2S,3R,4S)-5,6-BIS(4-HYDROXYPHENYL)-7-OXABICYCLO[2.2.1]HEPT-5-ENE-2,3-DICARBOXYLATE
  • 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE
  • 4-[(1S,2R,5S)-4,4,8-TRIMETHYL-3-OXABICYCLO[3.3.1]NON-7-EN-2-YL]PHENOL
  • (3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-9-OL
  • RALOXIFENE CORE
SRC SRC proto-oncogene, non-receptor tyrosine kinase
  • Signaling by ERBB2
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5\'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
AR androgen receptor
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Levonorgestrel
  • Spironolactone
  • Flutamide
  • Oxandrolone
  • Testosterone
  • Nilutamide
  • Fludrocortisone
  • Drostanolone
  • Nandrolone phenpropionate
  • Bicalutamide
  • Fluoxymesterone
  • Drospirenone
  • Danazol
  • Testosterone Propionate
  • Delta1-dihydrotestosterone
  • Boldenone
  • Calusterone
  • Flufenamic Acid
  • Dihydrotestosterone
  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide
  • Methyltrienolone
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE
  • Cyproterone
  • Methyltestosterone
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL
  • Nandrolone decanoate
  • Enzalutamide
CSNK2A1 casein kinase 2, alpha 1 polypeptide
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
TOP2A topoisomerase (DNA) II alpha 170kDa
  • G0 and Early G1
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Moxifloxacin
  • Amsacrine
  • Dexrazoxane
  • Valrubicin
  • Teniposide
  • Epirubicin
  • Enoxacin
  • Pefloxacin
  • Ciprofloxacin
  • Trovafloxacin
  • Daunorubicin
  • Etoposide
  • Lomefloxacin
  • Doxorubicin
  • Norfloxacin
  • Levofloxacin
  • Ofloxacin
  • Idarubicin
  • Podofilox
  • Mitoxantrone
  • Sparfloxacin
  • Genistein
  • Fleroxacin
  • Lucanthone
PGR progesterone receptor
  • Nuclear signaling by ERBB4
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • Signaling by ERBB4
  • Etonogestrel
  • Desogestrel
  • Megestrol
  • Levonorgestrel
  • Dydrogesterone
  • Progesterone
  • Fluticasone Propionate
  • Medroxyprogesterone
  • Norethindrone
  • Ethynodiol Diacetate
  • Mifepristone
  • Norgestimate
  • Drospirenone
  • Danazol
  • Allylestrenol
  • Methyltrienolone
  • Tanaproget
  • Norelgestromin
ABL1 ABL proto-oncogene 1, non-receptor tyrosine kinase
  • Role of Abl in Robo-Slit signaling
  • CDO in myogenesis
  • Axon guidance
  • Myogenesis
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • Signaling by Robo receptor
  • Regulation of actin dynamics for phagocytic cup formation
  • Innate Immune System
  • Adenosine triphosphate
  • Imatinib
  • Dasatinib
  • N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
  • Nilotinib
  • Bosutinib
  • 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
  • MYRISTIC ACID
  • 6-(2,6-DICHLOROPHENYL)-2-{[3-(HYDROXYMETHYL)PHENYL]AMINO}-8-METHYLPYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
  • 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
  • 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
  • Regorafenib
  • Ponatinib
LCK LCK proto-oncogene, Src family tyrosine kinase
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Nef and signal transduction
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Regulation of KIT signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • CD28 co-stimulation
  • Host Interactions of HIV factors
  • CD28 dependent PI3K/Akt signaling
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • TCR signaling
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • HIV Infection
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Nef Mediated CD4 Down-regulation
  • Innate Immune System
  • Signalling by NGF
  • Generation of second messenger molecules
  • Translocation of ZAP-70 to Immunological synapse
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • CTLA4 inhibitory signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • CD28 dependent Vav1 pathway
  • PECAM1 interactions
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • PD-1 signaling
  • GPVI-mediated activation cascade
  • Phosphorylation of CD3 and TCR zeta chains
  • Dasatinib
  • {4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • (4-{2-Acetylamino-2-[1-(3-Carbamoyl-4-Cyclohexylmethoxy-Phenyl)-Ethylcarbamoyl}-Ethyl}-2-Phosphono-Phenoxy)-Acetic Acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
AURKA aurora kinase A
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Regulation of mitotic cell cycle
  • G2/M Transition
  • Mitotic G2-G2/M phases
  • Regulation of PLK1 Activity at G2/M Transition
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • Phosphonothreonine
  • Adenosine-5\'-Diphosphate
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 8-ethyl-3,10,10-trimethyl-4,5,6,8,10,12-hexahydropyrazolo[4\',3\':6,7]cyclohepta[1,2-b]pyrrolo[2,3-f]indol-9(1H)-one
  • 1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea
  • 1-(3-chlorophenyl)-3-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}urea
  • 1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea
  • N-{3-[(4-{[3-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-2-YL)AMINO]PHENYL}CYCLOPROPANECARBOXAMIDE
  • N-butyl-3-{[6-(9H-purin-6-ylamino)hexanoyl]amino}benzamide
  • 2-(1H-pyrazol-3-yl)-1H-benzimidazole
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
CASP3 caspase 3, apoptosis-related cysteine peptidase
  • SMAC binds to IAPs
  • SMAC-mediated dissociation of IAP:caspase complexes
  • SMAC-mediated apoptotic response
  • Cytochrome c-mediated apoptotic response
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Degradation of the extracellular matrix
  • Role of DCC in regulating apoptosis
  • Activation of caspases through apoptosome-mediated cleavage
  • Activation of DNA fragmentation factor
  • Apoptotic factor-mediated response
  • Programmed Cell Death
  • Intrinsic Pathway for Apoptosis
  • Signalling by NGF
  • Apoptotic cleavage of cellular proteins
  • Cell death signalling via NRAGE, NRIF and NADE
  • Apoptotic execution phase
  • p75 NTR receptor-mediated signalling
  • Stimulation of the cell death response by PAK-2p34
  • Apoptotic cleavage of cell adhesion proteins
  • Signaling by Hippo
  • Apoptosis induced DNA fragmentation
  • Extrinsic Pathway
  • NADE modulates death signalling
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
CDK5 cyclin-dependent kinase 5
  • Signaling by GPCR
  • Axon guidance
  • Semaphorin interactions
  • Opioid Signalling
  • DARPP-32 events
  • CRMPs in Sema3A signaling
  • Factors involved in megakaryocyte development and platelet production
  • Indirubin-3\'-Monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Flavopiridol
  • Alsterpaullone
  • 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
TUBB tubulin, beta class I
  • Organelle biogenesis and maintenance
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Loss of Nlp from mitotic centrosomes
  • G2/M Transition
  • Assembly of the primary cilium
  • Centrosome maturation
  • Regulation of PLK1 Activity at G2/M Transition
  • Mitotic G2-G2/M phases
  • Anchoring of the basal body to the plasma membrane
  • Recruitment of mitotic centrosome proteins and complexes
  • Cell Cycle, Mitotic
  • Vinorelbine
  • Vincristine
  • Vinblastine
  • Podofilox
  • Colchicine
  • Epothilone D
  • Epothilone B
CDK1 cyclin-dependent kinase 1
  • Phosphorylation of the APC/C
  • Signaling by FGFR in disease
  • Phosphorylation of Emi1
  • Signaling by EGFRvIII in Cancer
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • SOS-mediated signalling
  • Mitotic G1-G1/S phases
  • SHC-mediated signalling
  • Recruitment of mitotic centrosome proteins and complexes
  • TRIF-mediated TLR3/TLR4 signaling
  • ERK1 activation
  • Nuclear Pore Complex (NPC) Disassembly
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • ERK1 activation
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Signaling by VEGF
  • Resolution of Sister Chromatid Cohesion
  • Downstream signal transduction
  • Signalling to RAS
  • Toll Like Receptor 3 (TLR3) Cascade
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • Interleukin-2 signaling
  • Mitotic G2-G2/M phases
  • Frs2-mediated activation
  • MASTL Facilitates Mitotic Progression
  • Axon guidance
  • IRS-mediated signalling
  • G2/M Transition
  • VEGFA-VEGFR2 Pathway
  • Activated TLR4 signalling
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • Cyclin A/B1 associated events during G2/M transition
  • Loss of Nlp from mitotic centrosomes
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Innate Immune System
  • Condensation of Prometaphase Chromosomes
  • Signaling by Insulin receptor
  • E2F mediated regulation of DNA replication
  • Insulin receptor signalling cascade
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • G0 and Early G1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • SHC-related events
  • Signaling by FGFR
  • ARMS-mediated activation
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • E2F-enabled inhibition of pre-replication complex formation
  • Regulation of mitotic cell cycle
  • Cell Cycle Checkpoints
  • Signaling by GPCR
  • G2/M Checkpoints
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • FCERI mediated MAPK activation
  • Regulation of PLK1 Activity at G2/M Transition
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • G1/S Transition
  • G1/S-Specific Transcription
  • Toll Like Receptor 9 (TLR9) Cascade
  • G2/M DNA replication checkpoint
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • APC/C-mediated degradation of cell cycle proteins
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Condensation of Prophase Chromosomes
  • Signaling by Leptin
  • Signalling to ERKs
  • Mitotic Prometaphase
  • Prolonged ERK activation events
  • Organelle biogenesis and maintenance
  • ERK activation
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Nuclear Envelope Breakdown
  • IGF1R signaling cascade
  • Recruitment of NuMA to mitotic centrosomes
  • Cyclin B2 mediated events
  • Toll Like Receptor TLR6:TLR2 Cascade
  • M Phase
  • IRS-related events triggered by IGF1R
  • MyD88 cascade initiated on plasma membrane
  • ERK activation
  • Downstream signaling of activated FGFR
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Signalling by NGF
  • SOS-mediated signalling
  • G2/M DNA damage checkpoint
  • MAP kinase activation in TLR cascade
  • SHC-mediated signalling
  • Depolymerisation of the Nuclear Lamina
  • Assembly of the primary cilium
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • MyD88-independent cascade
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • SHC1 events in EGFR signaling
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • FRS2-mediated cascade
  • IRS-mediated signalling
  • Centrosome maturation
  • Indirubin-3\'-Monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Flavopiridol
  • Alsterpaullone
AKT1 v-akt murine thymoma viral oncogene homolog 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Activation of BH3-only proteins
  • Signaling by Wnt
  • Platelet Aggregation (Plug Formation)
  • Signaling by EGFRvIII in Cancer
  • AKT phosphorylates targets in the cytosol
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Regulation of beta-cell development
  • PI3K/AKT activation
  • PI-3K cascade
  • RNF mutants show enhanced WNT signaling and proliferation
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • DAP12 interactions
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • GAB1 signalosome
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • G-protein beta:gamma signalling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Activation of BAD and translocation to mitochondria
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by VEGF
  • AKT phosphorylates targets in the nucleus
  • Downstream signal transduction
  • Regulation of gene expression in beta cells
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Costimulation by the CD28 family
  • PIP3 activates AKT signaling
  • Translocation of GLUT4 to the plasma membrane
  • deactivation of the beta-catenin transactivating complex
  • VEGFA-VEGFR2 Pathway
  • Metabolism of nitric oxide
  • G beta:gamma signalling through PI3Kgamma
  • PI3K events in ERBB2 signaling
  • VEGFR2 mediated vascular permeability
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Intrinsic Pathway for Apoptosis
  • Butyrate Response Factor 1 (BRF1) destabilizes mRNA
  • Innate Immune System
  • Signalling by NGF
  • CTLA4 inhibitory signaling
  • AKT-mediated inactivation of FOXO1A
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Negative regulation of the PI3K/AKT network
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by FGFR
  • eNOS activation
  • TCF dependent signaling in response to WNT
  • KSRP destabilizes mRNA
  • GPVI-mediated activation cascade
  • Signaling by WNT in cancer
  • Adenosine triphosphate
  • Arsenic trioxide
  • Inositol 1,3,4,5-Tetrakisphosphate
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
ALDH1A1 aldehyde dehydrogenase 1 family, member A1
  • Defective CYP2R1 causes Rickets vitamin D-dependent 1B (VDDR1B)
  • Metabolic disorders of biological oxidation enzymes
  • Ethanol oxidation
  • Phase 1 - Functionalization of compounds
  • Defective CYP27B1 causes Rickets vitamin D-dependent 1A (VDDR1A)
  • Defective CYP26C1 causes Focal facial dermal dysplasia 4 (FFDD4)
  • Defective CYP2U1 causes Spastic paraplegia 56, autosomal recessive (SPG56)
  • Biological oxidations
  • RA biosynthesis pathway
  • Defective FMO3 causes Trimethylaminuria (TMAU)
  • Defective TBXAS1 causes Ghosal hematodiaphyseal dysplasia (GHDD)
  • Defective CYP11A1 causes Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR)
  • Defective CYP27A1 causes Cerebrotendinous xanthomatosis (CTX)
  • Signaling by Retinoic Acid
  • Defective CYP11B1 causes Adrenal hyperplasia 4 (AH4)
  • Defective CYP26B1 causes Radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA)
  • Defective CYP1B1 causes Glaucoma
  • Defective CYP17A1 causes Adrenal hyperplasia 5 (AH5)
  • Defective CYP7B1 causes Spastic paraplegia 5A, autosomal recessive (SPG5A) and Congenital bile acid synthesis defect 3 (CBAS3)
  • Defective CYP19A1 causes Aromatase excess syndrome (AEXS)
  • Defective CYP4F22 causes Ichthyosis, congenital, autosomal recessive 5 (ARCI5)
  • Defective CYP24A1 causes Hypercalcemia, infantile (HCAI)
  • Defective MAOA causes Brunner syndrome (BRUNS)
  • Defective CYP11B2 causes Corticosterone methyloxidase 1 deficiency (CMO-1 deficiency)
  • Defective CYP21A2 causes Adrenal hyperplasia 3 (AH3)
  • NADH
  • Vitamin A
  • Tretinoin
  • Nicotinamide-Adenine-Dinucleotide
  • 1,4-Dithiothreitol
TUBA4A tubulin, alpha 4a
  • Transport of connexons to the plasma membrane
  • Hedgehog 'off' state
  • Platelet degranulation
  • Formation of tubulin folding intermediates by CCT/TriC
  • Regulation of PLK1 Activity at G2/M Transition
  • Prefoldin mediated transfer of substrate to CCT/TriC
  • Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding
  • Gap junction trafficking and regulation
  • Response to elevated platelet cytosolic Ca2+
  • Recruitment of mitotic centrosome proteins and complexes
  • Gap junction assembly
  • Gap junction trafficking
  • Factors involved in megakaryocyte development and platelet production
  • Resolution of Sister Chromatid Cohesion
  • Platelet activation, signaling and aggregation
  • Mitotic G2-G2/M phases
  • Mitotic Metaphase and Anaphase
  • Adaptive Immune System
  • Mitotic Prometaphase
  • Organelle biogenesis and maintenance
  • Axon guidance
  • Separation of Sister Chromatids
  • Translocation of GLUT4 to the plasma membrane
  • G2/M Transition
  • L1CAM interactions
  • Mitotic Anaphase
  • Recycling pathway of L1
  • Recruitment of NuMA to mitotic centrosomes
  • M Phase
  • Intraflagellar transport
  • Post-chaperonin tubulin folding pathway
  • Loss of Nlp from mitotic centrosomes
  • MHC class II antigen presentation
  • Protein folding
  • Kinesins
  • Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
  • Assembly of the primary cilium
  • Anchoring of the basal body to the plasma membrane
  • Cell Cycle, Mitotic
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Signaling by Hedgehog
  • Chaperonin-mediated protein folding
  • Centrosome maturation
  • Vincristine
  • Podofilox
  • Epothilone D
  • Epothilone B
  • Cabazitaxel
JUN jun proto-oncogene
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • FCERI mediated MAPK activation
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • Pre-NOTCH Transcription and Translation
  • MyD88 dependent cascade initiated on endosome
  • Pre-NOTCH Expression and Processing
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Signaling by NOTCH
  • TRIF-mediated TLR3/TLR4 signaling
  • MAP kinase activation in TLR cascade
  • Senescence-Associated Secretory Phenotype (SASP)
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Oxidative Stress Induced Senescence
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Fc epsilon receptor (FCERI) signaling
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Vinblastine
  • Irbesartan
  • Arsenic trioxide
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  • Signaling by the B Cell Receptor (BCR)
  • NF-kB is activated and signals survival
  • Downstream TCR signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Cellular Senescence
  • RIP-mediated NFkB activation via ZBP1
  • Toll Like Receptor TLR6:TLR2 Cascade
  • DEx/H-box helicases activate type I IFN and inflammatory cytokines production
  • Activated TLR4 signalling
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • FCERI mediated NF-kB activation
  • MyD88 cascade initiated on plasma membrane
  • Toll Like Receptor 5 (TLR5) Cascade
  • ZBP1(DAI) mediated induction of type I IFNs
  • p75NTR signals via NF-kB
  • Transcriptional regulation of white adipocyte differentiation
  • MyD88 dependent cascade initiated on endosome
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • MyD88:Mal cascade initiated on plasma membrane
  • Toll Like Receptor 9 (TLR9) Cascade
  • Innate Immune System
  • Regulated proteolysis of p75NTR
  • Signalling by NGF
  • TRIF-mediated TLR3/TLR4 signaling
  • Cytosolic sensors of pathogen-associated DNA
  • Senescence-Associated Secretory Phenotype (SASP)
  • Cytokine Signaling in Immune system
  • p75 NTR receptor-mediated signalling
  • MyD88-independent cascade
  • Toll Like Receptor 2 (TLR2) Cascade
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • Signaling by Interleukins
  • TCR signaling
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • Interleukin-1 processing
  • Toll Like Receptor 3 (TLR3) Cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Activation of NF-kappaB in B cells
  • Fc epsilon receptor (FCERI) signaling
  • TRAF6 mediated NF-kB activation
  • Interleukin-1 signaling
  • Adaptive Immune System
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Thalidomide
  • Pranlukast
  • Triflusal
CDK7 cyclin-dependent kinase 7
  • RNA Polymerase II Promoter Escape
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • RNA Polymerase II Transcription Pre-Initiation And Promoter Opening
  • RNA Polymerase I Chain Elongation
  • RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
  • Tat-mediated elongation of the HIV-1 transcript
  • Cyclin E associated events during G1/S transition
  • Formation of transcription-coupled NER (TC-NER) repair complex
  • Dual incision reaction in TC-NER
  • NoRC negatively regulates rRNA expression
  • G1/S Transition
  • Mitotic G1-G1/S phases
  • S Phase
  • Late Phase of HIV Life Cycle
  • Formation of RNA Pol II elongation complex
  • Global Genomic NER (GG-NER)
  • RNA Polymerase II Transcription Initiation And Promoter Clearance
  • Cyclin A:Cdk2-associated events at S phase entry
  • Mitotic G2-G2/M phases
  • Transcription of the HIV genome
  • Nucleotide Excision Repair
  • RNA Polymerase II Transcription
  • RNA Polymerase I Transcription Initiation
  • HIV Infection
  • RNA Polymerase I Promoter Clearance
  • Formation of the Early Elongation Complex
  • G2/M Transition
  • RNA Pol II CTD phosphorylation and interaction with CE
  • RNA Polymerase II Pre-transcription Events
  • HIV Transcription Initiation
  • HIV Life Cycle
  • RNA Pol II CTD phosphorylation and interaction with CE
  • Cyclin A/B1 associated events during G2/M transition
  • RNA Polymerase II HIV Promoter Escape
  • HIV Transcription Elongation
  • Dual incision reaction in GG-NER
  • RNA Polymerase I Transcription
  • mRNA Capping
  • RNA Polymerase I Promoter Escape
  • RNA Polymerase I Transcription Termination
  • G1 Phase
  • Epigenetic regulation of gene expression
  • Negative epigenetic regulation of rRNA expression
  • Cell Cycle, Mitotic
  • Cyclin D associated events in G1
  • Transcription-coupled NER (TC-NER)
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Formation of incision complex in GG-NER
  • RNA Polymerase II Transcription Initiation
  • RNA Polymerase II Transcription Elongation
  • Phosphonothreonine
  • Flavopiridol
DHPS deoxyhypusine synthase
  • Post-translational protein modification
  • Hypusine synthesis from eIF5A-lysine
  • Gamma carboxylation, hypusine formation and arylsulfatase activation
  • Nicotinamide-Adenine-Dinucleotide
  • 1-Guanidinium-7-Aminoheptane
HGF hepatocyte growth factor (hepapoietin A; scatter factor)
  • Signaling by Interleukins
  • Response to elevated platelet cytosolic Ca2+
  • Interleukin-7 signaling
  • Cytokine Signaling in Immune system
  • Platelet degranulation
  • Platelet activation, signaling and aggregation
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
PIK3R1 phosphoinositide-3-kinase, regulatory subunit 1 (alpha)
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by FGFR1 mutants
  • Interleukin-7 signaling
  • Role of phospholipids in phagocytosis
  • Phospholipid metabolism
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • PI3K Cascade
  • Signaling by PDGF
  • DAP12 interactions
  • GAB1 signalosome
  • G-protein beta:gamma signalling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • G alpha (q) signalling events
  • Signaling by ERBB2
  • Signaling by EGFR
  • GPCR downstream signaling
  • Signaling by Interleukins
  • TCR signaling
  • Signaling by VEGF
  • GP1b-IX-V activation signalling
  • Downstream signal transduction
  • Signaling by FGFR mutants
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Nephrin interactions
  • Interleukin-2 signaling
  • PI3K/AKT Signaling in Cancer
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Adaptive Immune System
  • G alpha (q) signalling events
  • Downstream TCR signaling
  • Costimulation by the CD28 family
  • IRS-mediated signalling
  • PIP3 activates AKT signaling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • Synthesis of PIPs at the plasma membrane
  • IRS-related events triggered by IGF1R
  • G beta:gamma signalling through PI3Kgamma
  • PI3K events in ERBB2 signaling
  • Regulation of signaling by CBL
  • Downstream signaling of activated FGFR
  • G alpha (12/13) signalling events
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • PI Metabolism
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • IRS-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • IRS-mediated signalling
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • GPVI-mediated activation cascade
  • Interleukin receptor SHC signaling
  • Signaling by FGFR1 fusion mutants
  • Constitutive Signaling by EGFRvIII
  • PI3K Cascade
  • Isoproterenol
  • (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
XIAP X-linked inhibitor of apoptosis, E3 ubiquitin protein ligase
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • SMAC binds to IAPs
  • SMAC-mediated dissociation of IAP:caspase complexes
  • SMAC-mediated apoptotic response
  • Signaling by Wnt
  • deactivation of the beta-catenin transactivating complex
  • Apoptotic factor-mediated response
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Programmed Cell Death
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Intrinsic Pathway for Apoptosis
  • 1-[3,3-Dimethyl-2-(2-Methylamino-Propionylamino)-Butyryl]-Pyrrolidine-2-Carboxylic Acid(1,2,3,4-Tetrahydro-Naphthalen-1-Yl)-Amide
  • N-METHYLALANYL-3-METHYLVALYL-4-PHENOXY-N-(1,2,3,4-TETRAHYDRONAPHTHALEN-1-YL)PROLINAMIDE
ACACA acetyl-CoA carboxylase alpha
  • Metabolism of vitamins and cofactors
  • Defective CD320 causes methylmalonic aciduria
  • Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF
  • Integration of energy metabolism
  • Metabolism of lipids and lipoproteins
  • ChREBP activates metabolic gene expression
  • Defective BTD causes biotidinase deficiency
  • Import of palmitoyl-CoA into the mitochondrial matrix
  • Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC
  • Defective MTR causes methylmalonic aciduria and homocystinuria type cblG
  • Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • Fatty Acyl-CoA Biosynthesis
  • Defective AMN causes hereditary megaloblastic anemia 1
  • Triglyceride Biosynthesis
  • Defects in cobalamin (B12) metabolism
  • Defective GIF causes intrinsic factor deficiency
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Defective HLCS causes multiple carboxylase deficiency
  • Defective MMAB causes methylmalonic aciduria type cblB
  • Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD
  • Defective MMAA causes methylmalonic aciduria type cblA
  • Defective CUBN causes hereditary megaloblastic anemia 1
  • Metabolism of water-soluble vitamins and cofactors
  • Defective MUT causes methylmalonic aciduria mut type
  • Defects in biotin (Btn) metabolism
  • Activation of gene expression by SREBF (SREBP)
  • Defective TCN2 causes hereditary megaloblastic anemia
  • Biotin transport and metabolism
  • Defects in vitamin and cofactor metabolism
  • Biotin
CCND1 cyclin D1
  • Chromatin organization
  • Signaling by NOTCH
  • Ubiquitin-dependent degradation of Cyclin D
  • G1 Phase
  • S Phase
  • Cell Cycle, Mitotic
  • RMTs methylate histone arginines
  • Ubiquitin-dependent degradation of Cyclin D1
  • Cyclin D associated events in G1
  • Chromatin modifying enzymes
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Expression and Processing
  • Mitotic G1-G1/S phases
  • Arsenic trioxide
COL1A1 collagen, type I, alpha 1
  • Platelet Adhesion to exposed collagen
  • Collagen formation
  • Collagen degradation
  • Anchoring fibril formation
  • Non-integrin membrane-ECM interactions
  • Degradation of the extracellular matrix
  • Assembly of collagen fibrils and other multimeric structures
  • Cell surface interactions at the vascular wall
  • Syndecan interactions
  • Crosslinking of collagen fibrils
  • ECM proteoglycans
  • GPVI-mediated activation cascade
  • Integrin cell surface interactions
  • Collagen biosynthesis and modifying enzymes
  • Platelet activation, signaling and aggregation
  • Scavenging by Class A Receptors
  • Collagenase
CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CUBN cubilin (intrinsic factor-cobalamin receptor)
  • Lipoprotein metabolism
  • Metabolism of vitamins and cofactors
  • Defective CD320 causes methylmalonic aciduria
  • Defective LMBRD1 causes methylmalonic aciduria and homocystinuria type cblF
  • Metabolism of lipids and lipoproteins
  • Defective BTD causes biotidinase deficiency
  • Defective MMACHC causes methylmalonic aciduria and homocystinuria type cblC
  • Defective MTR causes methylmalonic aciduria and homocystinuria type cblG
  • Defective MTRR causes methylmalonic aciduria and homocystinuria type cblE
  • Defective AMN causes hereditary megaloblastic anemia 1
  • Defects in cobalamin (B12) metabolism
  • Defective GIF causes intrinsic factor deficiency
  • Defective HLCS causes multiple carboxylase deficiency
  • Defective MMAB causes methylmalonic aciduria type cblB
  • Lipid digestion, mobilization, and transport
  • Defective MMADHC causes methylmalonic aciduria and homocystinuria type cblD
  • Metabolism of steroid hormones and vitamin D
  • Defective MMAA causes methylmalonic aciduria type cblA
  • Defective CUBN causes hereditary megaloblastic anemia 1
  • Cobalamin (Cbl, vitamin B12) transport and metabolism
  • HDL-mediated lipid transport
  • Defective MUT causes methylmalonic aciduria mut type
  • Metabolism of water-soluble vitamins and cofactors
  • Defects in biotin (Btn) metabolism
  • Defective TCN2 causes hereditary megaloblastic anemia
  • Vitamin D (calciferol) metabolism
  • Defects in vitamin and cofactor metabolism
  • Hydroxocobalamin
HIBADH 3-hydroxyisobutyrate dehydrogenase
  • Branched-chain amino acid catabolism
  • Metabolism of amino acids and derivatives
  • NADH
LCMT1 leucine carboxyl methyltransferase 1
  • L-Leucine
LDHC lactate dehydrogenase C
  • NADH
PISD phosphatidylserine decarboxylase
  • Metabolism of lipids and lipoproteins
  • Synthesis of PE
  • Phospholipid metabolism
  • Glycerophospholipid biosynthesis
  • Phosphatidylserine
PSAP prosaposin
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • Sphingolipid metabolism
  • Metabolism of lipids and lipoproteins
  • Glycosphingolipid metabolism
  • Class A/1 (Rhodopsin-like receptors)
  • Platelet degranulation
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Peptide ligand-binding receptors
  • Response to elevated platelet cytosolic Ca2+
  • Platelet activation, signaling and aggregation
  • Di-Stearoyl-3-Sn-Phosphatidylethanolamine
TARS threonyl-tRNA synthetase
  • Cytosolic tRNA aminoacylation
  • tRNA Aminoacylation
  • L-Threonine